Finasteride may improve prostate cancer therapy by enhancing testosterone's benefits and reducing risks.
52 citations
,
July 1998 in “Urology” Liarozole may be more effective than cyproterone acetate for treating advanced prostate cancer, with better PSA response and survival rates, while maintaining quality of life.
May 2008 in “Trends in Urology Gynaecology & Sexual Health” Loop diuretics may double bone loss in elderly men, finasteride lowers prostate cancer risk but may increase high-grade tumors, abarelix reduces testosterone quickly, and transdermal testosterone offers minimal sexual benefit for women.
402 citations
,
August 2011 in “Cancer research” Prostate cancer cells can make their own androgens to activate the androgen receptor, and treatments like abiraterone may increase this ability, suggesting new therapies should target the entire steroid-making pathway.
9 citations
,
March 1991 in “Endocrinology” Using two drugs together, Flutamide and 4-MA, is more effective for blocking male hormones than using each one alone.
September 2023 in “SKIN The Journal of Cutaneous Medicine” Talquetamab may cause hair loss and skin issues.
November 2005 in “The Journal of Urology”
January 2023 in “Bioorganičeskaâ himiâ” The new compound is a promising, less toxic alternative to finasteride for treating prostate issues.
April 2026 in “Frontiers in Medicine” Enfortumab vedotin can cause skin issues, especially in older males, needing early monitoring.
45 citations
,
January 2012 in “The Journal of Steroid Biochemistry and Molecular Biology” Too much AKR1C3 enzyme causes resistance to finasteride by increasing testosterone.
The FDA did not approve a testosterone drug because of safety concerns.
12 citations
,
August 2018 in “Psychiatry research” Estazolam reduces anxiety-like behavior in PTSD by increasing allopregnanolone levels.
February 2026 in “Clinical and Experimental Dermatology” Bicalutamide improved hair growth more than spironolactone in women with hair loss.
1 citations
,
October 2020 in “Current Drug Discovery Technologies” The research found that compound 6, a newly created steroid, is more effective at inhibiting 5α-reductase (an enzyme) than current treatments, suggesting it could be a better option for treating urinary tract symptoms in men.
August 2022 in “Nature Biotechnology” Drug approvals slowed in 2Q22, but notable drugs like Amvuttra, Camzyos, and Olumiant were approved.
June 2019 in “Reactions Weekly” 3 citations
,
February 2019 in “Molecular genetics and metabolism” The combination of tadalafil and finasteride improves urinary symptoms and erectile function in men with enlarged prostates.
20 citations
,
May 2011 in “Cancer Biology & Therapy” Finasteride may improve prostate cancer treatment outcomes.
March 2014 in “The Journal of Urology” Long-term treatment with finasteride or combined therapy worsens sexual function in men with urinary issues.
January 2025 in “Journal of the American Academy of Dermatology” Combining oral minoxidil and bicalutamide may help improve hair growth in adolescent girls.
10 citations
,
December 2005 in “Aktuelle Dermatologie” Alfatradiol (0.025%) is an effective and safe treatment for hair loss in both women and men.
January 2025 in “Reactions Weekly” November 2024 in “Reactions Weekly” May 2023 in “Reactions Weekly” January 2004 in “Drug Development and Industrial Pharmacy” GI197111X is best dissolved in Capmul MCM for trials.
23 citations
,
December 2013 in “Molecular cancer therapeutics” Breast cancer treatments work better with AR activation, improving results and reducing side effects.
August 2002 in “Inpharma Weekly”
7 citations
,
January 2021 in “The Journal of Sexual Medicine” Testosterone with dutasteride improves muscle strength and body composition in trans men.
3 citations
,
September 2021 in “JAAD case reports” Denosumab, a bone loss treatment, may cause hair loss and skin reactions due to immune system effects.